In a historic development for HIV treatment worldwide, Dr. Reddy’s Laboratories has announced a new partnership with Gilead Sciences to manufacture and commercialize a revolutionary drug called Lenacapavir. This voluntary licensing agreement, unveiled on October 2, 2024, grants Dr. Reddy’s rights to produce and market the drug in India and 120 other countries. The collaboration […]
Dr. Reddy’s Laboratories, the Indian pharmaceutical giant, has solidified its European ambitions with a monumental $620 million investment in its Switzerland-based subsidiary, Dr. Reddy’s Laboratories SA. This strategic injection of capital is set to transform the company’s European footprint, further fueling its expansion into the lucrative consumer healthcare market. At the core of this investment […]
In a significant development for the pharmaceutical industry, Dr. Reddy’s Laboratories Ltd. has received a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) regarding its proposed biosimilar, DRL_RI, also known as ITUXREDI. This endorsement could pave the way for the launch of this promising biosimilar across European […]
Haleon plc, a prominent player in the global healthcare market, has reached an agreement to sell its nicotine replacement therapy (NRT) business outside of the United States to Dr. Reddy’s Laboratories SA, a subsidiary of Dr. Reddy’s Laboratories Limited. The deal, valued at £500 million, marks a strategic shift for Haleon, allowing it to streamline […]
Dr. Reddy’s Laboratories Ltd., a globally recognized pharmaceutical company, has unveiled DailyBloom IBS, marking a significant advancement in the management of Irritable Bowel Syndrome (IBS) in India. Launched on World IBS Day, DailyBloom IBS is the first comprehensive care plan in India tailored specifically for IBS, incorporating a mobile application developed in-house for continuous care. […]
In an exciting development for migraine sufferers, Dr. Reddy’s Laboratories Ltd., a leader in the global pharmaceutical industry, has announced the launch of its groundbreaking, drug-free, non-invasive migraine management device, Nerivio, in Germany. This move, facilitated through its step-down subsidiary betapharm, signifies Dr. Reddy’s Laboratories’ foray into the realm of digital therapeutics in Europe, marking […]
Dr. Reddy’s Laboratories Ltd., a leading global pharmaceutical company, has made significant strides in cancer treatment with the introduction of Versavo (bevacizumab) in the United Kingdom (UK). This landmark launch brings a biosimilar of Avastin, indicated for the treatment of a wide range of cancers, to the UK market. Versavo represents a beacon of hope […]
In a significant move within the healthcare industry, Dr. Reddy’s Laboratories Ltd. has announced the acquisition of the MenoLabs business, a prominent player in women’s health and dietary supplements, from Amyris, Inc. This acquisition occurred during Amyris’ Chapter 11 sales process. At the forefront of this deal is the entire portfolio of MenoLabs supplements, which […]
Coya Therapeutics, Inc. (NASDAQ: COYA), a clinical-stage biotechnology company, has entered into a worldwide agreement with Dr. Reddy’s Laboratories Limited, a global pharmaceutical leader, marking a significant advancement in the treatment of neurodegenerative diseases. This collaboration focuses on the development of COYA 302, a dual biologic designed to combat neuroinflammation and treat various neurodegenerative conditions. […]
Dr. Reddy’s Laboratories Ltd., a global pharmaceutical company, has announced the rollout of Nerivio in India. This state-of-the-art, United States Food and Drug Administration (USFDA) approved wearable therapy device offers a drug-free option for managing migraines. Migraine is a prevalent global health challenge, significantly impacting women, who make up about 60% of the 213 million […]